Sign up
Pharma Capital

Integumen PLC to make 'transformational' move into clinical trials

Integumen PLC (LON:SKIN) CEO Gerry Brandon speaks to Proactive London's Andrew Scott soon after announcing the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical trials.

He says the new test will cut the number of volunteers required for trials by 50%, reduce recruitment times and project management costs as well as make them more reliable and accurate.


View full SKIN profile View Profile

Integumen's digital revolution

View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.